NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
Reveal Pharmaceuticals Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mercy Research
University Health Network, Toronto
NYU Langone Health
Seoul National University Hospital
National Institutes of Health Clinical Center (CC)